Symbols / TVGN $5.58 +3.72%
TVGN Chart
About
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 22.59M |
| Enterprise Value | 37.47M | Income | -31.42M | Sales | — |
| Book/sh | -4.21 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | 18 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | -1.33 | P/C | — |
| EV/EBITDA | -1.22 | EV/Sales | — | Quick Ratio | 0.18 |
| Current Ratio | 0.32 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -9.00 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -4.40% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.05M |
| Shs Float | 572.19K | Short Float | 4.90% | Short Ratio | 4.08 |
| Short Interest | — | 52W High | 75.50 | 52W Low | 4.92 |
| Beta | -0.75 | Avg Volume | 22.03K | Volume | 75.92K |
| Target Price | — | Recom | Hold | Prev Close | $5.38 |
| Price | $5.58 | Change | 3.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$5.58
Latest analyst target
3. DCF / Fair value
$-3.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.58
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | down | D. Boral Capital | Buy → Hold | — |
| 2026-03-03 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-11-20 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-04 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-06 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-04 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-10 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-27 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-21 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-11 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-04 | init | D. Boral Capital | — → Buy | $10 |
- Tevogen keeps float tight, weighs special dividend and $50M revenue buys - Stock Titan Fri, 13 Mar 2026 18
- Tevogen Bio (TVGN) Stock Pre-Market (-4.1%): New Diversified Strategy Met With Skepticism - Trefis Wed, 11 Mar 2026 12
- Tevogen Bio Accelerates Development of TVGN 489 for Long COVID with New Leadership and Strategic Initiatives - Quiver Quantitative Wed, 11 Mar 2026 19
- Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - simplywall.st hu, 08 Jan 2026 08
- Tevogen Announces Reverse Stock Split - GlobeNewswire Wed, 04 Mar 2026 08
- Inside the AI model Tevogen is training to cut trial-and-error in drug R&D - Stock Titan Fri, 13 Mar 2026 16
- Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance ue, 09 Dec 2025 08
- Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization - Finviz Fri, 13 Mar 2026 20
- Tevogen Bio Stock Pre-Market (-7.0%): 1-for-50 Reverse Split Becomes Effective - Trefis Sat, 07 Mar 2026 12
- Tevogen (NASDAQ: TVGN) approves reverse split and 100M plan increase - Stock Titan hu, 26 Feb 2026 08
- Tevogen explores digital care deal that would make it revenue-generating - Stock Titan hu, 26 Feb 2026 08
- Inside Tevogen's $50M expansion push and the team picked to run it - Stock Titan Mon, 09 Mar 2026 11
- Tevogen to swap every 50 shares for 1 in bid to meet Nasdaq rules - Stock Titan Wed, 04 Mar 2026 08
- Tevogen Bio explores acquisitions that may add $50M+ in yearly revenue - Stock Titan Fri, 06 Mar 2026 20
- Tevogen weighs CRO acquisition to add service revenue, optimize trials - Stock Titan Fri, 27 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | — | — | Stock Gift at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 1 | 460000 | — | — | Stock Gift at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
| 2 | 300000 | — | — | Stock Gift at price 0.00 per share. | DESAI KIRTI | Chief Financial Officer | — | 2025-12-11 00:00:00 | D |
| 3 | 20000 | — | — | Stock Gift at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-08-15 00:00:00 | D |
| 4 | 200000 | — | — | Stock Award(Grant) at price 0.00 per share. | KHAN SADIQ | Officer | — | 2025-06-27 00:00:00 | D |
| 5 | 8000000 | — | — | Stock Award(Grant) at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-06-27 00:00:00 | D |
| 6 | 750000 | — | — | Stock Award(Grant) at price 0.00 per share. | DESAI KIRTI | Chief Financial Officer | — | 2025-06-27 00:00:00 | D |
| 7 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | FLOMENBERG NEAL | Officer | — | 2025-06-27 00:00:00 | D |
| 8 | 1438206 | 1768993 | — | Sale at price 1.23 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-06-09 00:00:00 | D |
| 9 | 232968 | 253935 | — | Sale at price 1.09 per share. | FLOMENBERG NEAL | Officer | — | 2025-03-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 1.13M | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -4.69M | -58.89M | -953.08K | -14.99M |
| TotalUnusualItems | -8.45M | 0.00 | 5.36M | |
| TotalUnusualItemsExcludingGoodwill | -8.45M | 0.00 | 5.36M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.73M | -60.48M | 4.41M | -15.60M |
| ReconciledDepreciation | 403.58K | 378.36K | 230.82K | 9.38K |
| EBITDA | -13.14M | -58.89M | 4.41M | -14.99M |
| EBIT | -13.54M | -59.27M | 4.41M | -15.00M |
| NetInterestIncome | -184.04K | -1.21M | 0.00 | -598.50K |
| InterestExpense | 184.04K | 1.21M | 0.00 | 598.50K |
| NormalizedIncome | -5.28M | -60.48M | 172.82K | -15.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.73M | -60.48M | 4.41M | -15.60M |
| TotalExpenses | 53.56M | 8.84M | 953.08K | 4.62M |
| TotalOperatingIncomeAsReported | -53.56M | -8.84M | -13.72M | -4.62M |
| DilutedAverageShares | 2.93M | 3.31M | 2.40M | 2.40M |
| BasicAverageShares | 2.93M | 3.31M | 2.40M | 2.40M |
| DilutedEPS | -3.50 | -19.12 | 1.84 | -6.50 |
| BasicEPS | -3.50 | -19.12 | 1.84 | -6.50 |
| DilutedNIAvailtoComStockholders | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncomeCommonStockholders | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncome | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncomeIncludingNoncontrollingInterests | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncomeContinuousOperations | -13.73M | -60.48M | 4.41M | -15.60M |
| PretaxIncome | -13.73M | -60.48M | 4.41M | -15.60M |
| OtherIncomeExpense | 40.02M | -50.43M | 5.36M | -10.38M |
| OtherNonOperatingIncomeExpenses | 48.47M | -50.43M | -7.38M | -10.38M |
| SpecialIncomeCharges | -7.50M | 0.00 | 0.00 | |
| WriteOff | 250.00K | 0.00 | ||
| RestructuringAndMergernAcquisition | 7.50M | 0.00 | ||
| GainOnSaleOfSecurity | -948.18K | 2.71M | 5.36M | |
| NetNonOperatingInterestIncomeExpense | -184.04K | -1.21M | 0.00 | -598.50K |
| InterestExpenseNonOperating | 184.04K | 1.21M | 0.00 | 598.50K |
| OperatingIncome | -53.56M | -8.84M | -953.08K | -4.62M |
| OperatingExpense | 53.56M | 8.84M | 953.08K | 4.62M |
| ResearchAndDevelopment | 31.03M | 4.40M | 5.77M | 2.96M |
| SellingGeneralAndAdministration | 22.53M | 4.44M | 953.08K | 1.66M |
| GeneralAndAdministrativeExpense | 22.53M | 4.44M | 953.08K | 1.66M |
| OtherGandA | 7.05M | 3.34M | 953.08K | 898.09K |
| SalariesAndWages | 15.48M | 1.10M | 5.80M | 764.52K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.56M | 3.31M | 3.16M | 3.16M |
| ShareIssued | 3.56M | 3.31M | 3.16M | 3.16M |
| NetDebt | 1.37M | 93.88M | 33.81M | 16.36M |
| TotalDebt | 2.89M | 95.42M | 40.01M | 23.48M |
| TangibleBookValue | -15.47M | -94.43M | 342.08M | -16.49M |
| InvestedCapital | -12.82M | 503.10K | 342.08M | 6.99M |
| WorkingCapital | -6.68M | -83.76M | -76.10K | 6.51M |
| NetTangibleAssets | -6.67M | -94.43M | 342.08M | -16.49M |
| CapitalLeaseObligations | 234.86K | 487.57K | 710.93K | 0.00 |
| CommonStockEquity | -15.47M | -94.43M | 342.08M | -16.49M |
| PreferredStockEquity | 8.80M | |||
| TotalCapitalization | -5.67M | -80.21M | 342.08M | 6.99M |
| TotalEquityGrossMinorityInterest | -6.67M | -94.43M | 342.08M | -16.49M |
| StockholdersEquity | -6.67M | -94.43M | 342.08M | -16.49M |
| RetainedEarnings | -113.39M | -99.66M | -14.78M | -17.14M |
| AdditionalPaidInCapital | 97.89M | 5.22M | 5.17M | 586.23K |
| CapitalStock | 8.82M | 12.00K | 356.87M | 63.88K |
| CommonStock | 17.80K | 12.00K | 356.87M | 63.88K |
| PreferredStock | 8.80M | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 10.14M | 99.93M | 15.06M | 24.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.09M | 14.45M | 14.71M | 23.48M |
| DerivativeProductLiabilities | 87.18K | 0.00 | 7.25K | |
| NonCurrentDeferredLiabilities | 14.70M | 14.70M | ||
| LongTermDebtAndCapitalLeaseObligation | 1.01M | 14.45M | 39.73M | 23.48M |
| LongTermCapitalLeaseObligation | 5.80K | 234.86K | 432.73K | 0.00 |
| LongTermDebt | 1.00M | 14.22M | 39.30M | 23.48M |
| CurrentLiabilities | 9.04M | 85.48M | 350.45K | 667.94K |
| OtherCurrentLiabilities | 403.23K | 120.15K | 237.60K | 45.27K |
| CurrentDebtAndCapitalLeaseObligation | 1.88M | 80.96M | 278.21K | |
| CurrentCapitalLeaseObligation | 229.06K | 252.71K | 278.21K | 0.00 |
| CurrentDebt | 1.65M | 80.71M | ||
| OtherCurrentBorrowings | 80.71M | |||
| CurrentNotesPayable | 1.65M | 0.00 | ||
| PayablesAndAccruedExpenses | 6.76M | 4.39M | 350.45K | 622.68K |
| CurrentAccruedExpenses | 1.31M | 976.30K | 578.77K | 244.68K |
| Payables | 5.45M | 3.42M | 350.45K | 378.00K |
| DuetoRelatedPartiesCurrent | 250.00K | 0.00 | 140.00K | |
| AccountsPayable | 5.20M | 3.42M | 210.45K | 378.00K |
| TotalAssets | 3.46M | 5.51M | 357.14M | 7.66M |
| TotalNonCurrentAssets | 1.10M | 3.78M | 356.86M | 485.27K |
| OtherNonCurrentAssets | 575.84K | 271.14K | 356.86M | 342.65K |
| NonCurrentDeferredAssets | 0.00 | 2.58M | ||
| NetPPE | 524.93K | 928.51K | 1.31M | 142.62K |
| AccumulatedDepreciation | -425.33K | -263.12K | -99.82K | -9.38K |
| GrossPPE | 950.26K | 1.19M | 1.41M | 152.00K |
| Leases | 263.22K | 263.22K | 263.22K | 0.00 |
| OtherProperties | 228.49K | 469.86K | 684.92K | |
| MachineryFurnitureEquipment | 458.55K | 458.55K | 458.55K | 152.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.36M | 1.72M | 274.36K | 7.17M |
| OtherCurrentAssets | 919.09K | 670.58K | 145.17K | 53.96K |
| Receivables | 158.82K | 0.00 | 0.00 | |
| DuefromRelatedPartiesCurrent | 158.82K | 0.00 | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 1.28M | 1.05M | 129.19K | 7.12M |
| CashAndCashEquivalents | 1.28M | 1.05M | 129.19K | 7.12M |
| CashFinancial | 1.28M | 1.05M | 129.19K | 7.12M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.00M | -8.30M | -215.40K | -5.38M |
| RepurchaseOfCapitalStock | -342.98M | 0.00 | ||
| IssuanceOfDebt | 1.00M | 4.00M | 0.00 | 12.50M |
| IssuanceOfCapitalStock | 11.00M | 0.00 | ||
| CapitalExpenditure | -133.00K | -479.04K | -109.73K | |
| EndCashPosition | 1.28M | 1.05M | 129.19K | 7.12M |
| BeginningCashPosition | 1.05M | 5.48M | 344.58K | 3.84K |
| ChangesInCash | 230.60K | -4.43M | -215.40K | 7.12M |
| FinancingCashFlow | 12.23M | 3.87M | 0.00 | 12.50M |
| CashFlowFromContinuingFinancingActivities | 12.23M | 3.87M | 0.00 | 12.50M |
| NetOtherFinancingCharges | 229.33K | -127.75K | ||
| NetPreferredStockIssuance | 11.00M | 0.00 | ||
| PreferredStockIssuance | 11.00M | 0.00 | ||
| NetCommonStockIssuance | -342.98M | 0.00 | ||
| CommonStockPayments | -342.98M | 0.00 | ||
| NetIssuancePaymentsOfDebt | 1.00M | 4.00M | 0.00 | 12.50M |
| NetShortTermDebtIssuance | 1.32M | 0.00 | ||
| ShortTermDebtIssuance | 1.32M | 0.00 | ||
| NetLongTermDebtIssuance | 1.00M | 4.00M | 0.00 | 12.50M |
| LongTermDebtIssuance | 1.00M | 4.00M | 0.00 | 12.50M |
| InvestingCashFlow | 0.00 | -133.00K | 0.00 | -109.73K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -133.00K | 0.00 | -109.73K |
| NetOtherInvestingChanges | 342.92M | |||
| NetPPEPurchaseAndSale | 0.00 | -133.00K | -479.04K | -109.73K |
| PurchaseOfPPE | 0.00 | -133.00K | -479.04K | -109.73K |
| OperatingCashFlow | -12.00M | -8.17M | -215.40K | -5.27M |
| CashFlowFromContinuingOperatingActivities | -12.00M | -8.17M | -215.40K | -5.27M |
| ChangeInWorkingCapital | -5.49K | 293.20K | 737.69K | -1.25M |
| ChangeInOtherCurrentLiabilities | -252.71K | -223.36K | -114.37K | 0.00 |
| ChangeInOtherCurrentAssets | -511.01K | 323.74K | -252.24K | -342.65K |
| ChangeInPayablesAndAccruedExpense | 1.00M | 510.43K | 291.08K | -852.33K |
| ChangeInAccruedExpense | -681.45K | -603.83K | 568.70K | 240.27K |
| ChangeInPayable | 1.69M | 1.11M | 291.08K | -1.09M |
| ChangeInAccountPayable | 1.69M | 1.11M | 171.08K | -1.09M |
| ChangeInPrepaidAssets | -246.00K | -317.61K | 446.61K | -53.96K |
| ChangeInReceivables | -267.00K | 0.00 | ||
| OtherNonCashItems | -39.49M | 51.63M | 8.32M | 10.98M |
| StockBasedCompensation | 40.76M | 0.00 | 4.58M | 582.41K |
| UnrealizedGainLossOnInvestmentSecurities | -2.73M | -4.95M | ||
| AssetImpairmentCharge | 250.00K | |||
| DepreciationAmortizationDepletion | 403.58K | 378.36K | 230.82K | 9.38K |
| DepreciationAndAmortization | 403.58K | 378.36K | 230.82K | 9.38K |
| Depreciation | 403.58K | 378.36K | 230.82K | 9.38K |
| OperatingGainsLosses | 58.18K | 21.75K | -413.25K | |
| GainLossOnInvestmentSecurities | 58.18K | 21.75K | -413.25K | |
| NetIncomeFromContinuingOperations | -13.73M | -60.48M | 4.41M | -15.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TVGN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|